VolitionRX Ltd Company Profile (NYSEMKT:VNRX)

About VolitionRX Ltd (NYSEMKT:VNRX)

VolitionRX Ltd logoVolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Diagnostic & Testing Substances
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:VNRX
  • CUSIP: N/A
  • Web: www.volitionrx.com/
Capitalization:
  • Market Cap: $63.11 million
  • Outstanding Shares: 26,518,000
Average Prices:
  • 50 Day Moving Avg: $2.70
  • 200 Day Moving Avg: $3.20
  • 52 Week Range: $2.28 - $5.45
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.18
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.63 per share
  • Price / Book: 3.78
Profitability:
  • EBITDA: ($13,230,000.00)
  • Return on Equity: -79.20%
  • Return on Assets: -63.86%
Misc:
  • Average Volume: 37,823 shs.
  • Beta: -1.58
  • Short Ratio: 3.43
 

Frequently Asked Questions for VolitionRX Ltd (NYSEMKT:VNRX)

What is VolitionRX Ltd's stock symbol?

VolitionRX Ltd trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "VNRX."

How were VolitionRX Ltd's earnings last quarter?

VolitionRX Ltd (NYSEMKT:VNRX) announced its quarterly earnings results on Thursday, May, 11th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. View VolitionRX Ltd's Earnings History.

When will VolitionRX Ltd make its next earnings announcement?

VolitionRX Ltd is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for VolitionRX Ltd.

Where is VolitionRX Ltd's stock going? Where will VolitionRX Ltd's stock price be in 2017?

1 equities research analysts have issued 12-month target prices for VolitionRX Ltd's shares. Their predictions range from $10.00 to $10.00. On average, they expect VolitionRX Ltd's stock price to reach $10.00 in the next twelve months. View Analyst Ratings for VolitionRX Ltd.

Who are some of VolitionRX Ltd's key competitors?

Who are VolitionRX Ltd's key executives?

VolitionRX Ltd's management team includes the folowing people:

  • Martin Charles Faulkes, Executive Chairman of the Board
  • Cameron John Reynolds, President, Chief Executive Officer, Director
  • David Vanston, Chief Financial Officer, Treasurer
  • Louise Dayas, Chief Marketing and Communications Officer
  • Jason Bradley Terrell, Chief Medical Officer and Head of US Operations
  • Rodney Gerard Rootsaert, Secretary
  • Alan Colman, Director
  • Edward W. Futcher Ph.D., Independent Director
  • Guy Archibald Innes, Independent Director
  • Habib Skaff, Independent Director

How do I buy VolitionRX Ltd stock?

Shares of VolitionRX Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VolitionRX Ltd's stock price today?

One share of VolitionRX Ltd stock can currently be purchased for approximately $2.38.


MarketBeat Community Rating for VolitionRX Ltd (NYSEMKT VNRX)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  68 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  93
MarketBeat's community ratings are surveys of what our community members think about VolitionRX Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for VolitionRX Ltd (NYSEMKT:VNRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00
Consensus Price Target History for VolitionRX Ltd (NYSEMKT:VNRX)
Price Target History for VolitionRX Ltd (NYSEMKT:VNRX)
Analysts' Ratings History for VolitionRX Ltd (NYSEMKT:VNRX)
Show:
DateFirmActionRatingPrice TargetDetails
9/20/2017HC WainwrightReiterated RatingBuy$10.00View Rating Details
9/7/2016Rodman & RenshawLower Price TargetBuy$12.00 -> $10.00View Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for VolitionRX Ltd (NYSEMKT:VNRX)
Earnings by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
Earnings History by Quarter for VolitionRX Ltd (NYSEMKT VNRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017        
5/11/20173/31/2017($0.14)($0.13)ViewN/AView Earnings Details
8/11/2016Q216($0.12)($0.13)ViewListenView Earnings Details
5/13/2016Q116($0.13)($0.13)ViewN/AView Earnings Details
11/4/2015Q315($0.13)($0.16)$0.20 millionViewN/AView Earnings Details
8/11/2015Q215($0.14)($0.10)$0.11 millionViewN/AView Earnings Details
5/12/2015Q115($0.14)($0.12)ViewN/AView Earnings Details
11/6/2014($0.09)($0.13)$0.13 million$0.02 millionViewN/AView Earnings Details
5/27/2014($0.10)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for VolitionRX Ltd (NYSEMKT:VNRX)
Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS

Dividends

Dividend History for VolitionRX Ltd (NYSEMKT:VNRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for VolitionRX Ltd (NYSEMKT:VNRX)
Insider Trades by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
Institutional Ownership by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
Insider Trades by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/19/2017David Cecil VanstonInsiderBuy2,750$2.84$7,810.00View SEC Filing  
8/16/2017Cameron John ReynoldsInsiderBuy3,630$2.77$10,055.10View SEC Filing  
10/5/2016David Matthew KratochvilCFOBuy10,000$5.00$50,000.00View SEC Filing  
5/20/2016Cameron John ReynoldsCEOSell3,390$3.54$12,000.60View SEC Filing  
5/15/2015Cameron John ReynoldsCEOBuy1,500$3.33$4,995.00View SEC Filing  
2/11/2015Guy Archibald InnesDirectorBuy50,000$3.75$187,500.00View SEC Filing  
9/15/2014Martin Charles FaulkesDirectorBuy5,000$2.16$10,800.00View SEC Filing  
9/3/2014Rodney Gerard RootsaertInsiderSell28,000$1.80$50,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for VolitionRX Ltd (NYSEMKT:VNRX)
Latest Headlines for VolitionRX Ltd (NYSEMKT:VNRX)
Source:
DateHeadline
finance.yahoo.com logoVolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding
finance.yahoo.com - September 23 at 10:51 AM
finance.yahoo.com logoVolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits
finance.yahoo.com - September 23 at 10:51 AM
americanbankingnews.com logoHC Wainwright Reaffirms Buy Rating for VolitionRX Ltd (VNRX)
www.americanbankingnews.com - September 20 at 5:10 PM
finance.yahoo.com logoVolitionRx Announces its European Colorectal Cancer Strategy
finance.yahoo.com - September 19 at 8:25 PM
finance.yahoo.com logoVolition Granted Four Additional Patents
finance.yahoo.com - September 15 at 11:04 AM
finance.yahoo.com logoVolitionRx to Attend Two Major Conferences in Asia
finance.yahoo.com - September 15 at 11:03 AM
finance.yahoo.com logoVolitionRx Limited to Attend Multiple Conferences in September
finance.yahoo.com - September 7 at 10:56 AM
finance.yahoo.com logoVNRX: Pathway Design Study Progressing. Expect European Launch in 2018
finance.yahoo.com - August 30 at 3:47 PM
finance.yahoo.com logoVolition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers
finance.yahoo.com - August 23 at 1:38 PM
americanbankingnews.com logoCameron John Reynolds Purchases 3,630 Shares of VolitionRX Ltd (VNRX) Stock
www.americanbankingnews.com - August 17 at 9:16 PM
americanbankingnews.com logoVolitionRX Ltd (VNRX) PT Set at $10.00 by HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM
finance.yahoo.com logoVolitionRX reports 2Q loss
finance.yahoo.com - August 10 at 3:38 PM
finance.yahoo.com logoVolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update
finance.yahoo.com - August 10 at 9:29 AM
finance.yahoo.com logoVolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update
finance.yahoo.com - August 4 at 9:45 AM
americanbankingnews.com logoVolitionRX Ltd (VNRX) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - August 3 at 7:10 AM
americanbankingnews.com logoVolitionRX Ltd (VNRX) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - July 21 at 7:50 AM
finance.yahoo.com logoVolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute
finance.yahoo.com - July 19 at 9:11 PM
finance.yahoo.com logoVolition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute
finance.yahoo.com - July 18 at 9:46 AM
finance.yahoo.com logoVolition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress
finance.yahoo.com - July 1 at 8:52 AM
us.rd.yahoo.com logoVolition America, Inc. Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States
us.rd.yahoo.com - March 28 at 10:42 PM
us.rd.yahoo.com logoVolitionRx Limited Announces Full Fiscal Year 2016 Financial Results and Business Update
us.rd.yahoo.com - March 10 at 9:35 AM
biz.yahoo.com logoQ4 2016 VolitionRX Ltd Earnings Release - Before Market Open
us.rd.yahoo.com - March 10 at 9:35 AM
cnbc.com logoVolitionRX reports 4Q loss
www.cnbc.com - March 10 at 9:33 AM
us.rd.yahoo.com logoVolitionRx Limited's Triage Test Results Validated in Prospective Trial
us.rd.yahoo.com - February 25 at 8:05 PM
us.rd.yahoo.com logoVolitionRx Limited's Novel Cancer Diagnostic Test Achieves CE Marking as it Prepares for Launch Across Europe
us.rd.yahoo.com - January 4 at 7:38 AM
us.rd.yahoo.com logo9:03 am VolitionRx achieved CE marking on its Nu.Q Colorectal Cancer Screening Triage Test on December 28, 2016 as it prepares to launch across Europe
us.rd.yahoo.com - January 4 at 7:38 AM
prnewswire.com logoTriage Blood Test Data Presented to Leading International Experts at the World Endoscopy Organization's Colorectal Cancer Screening Committee
www.prnewswire.com - October 17 at 7:52 PM
streetinsider.com logoVolitionrx Limited (VNRX) Announces Presentation of Positive Blood Test for Colorectal Cancer Data
www.streetinsider.com - October 12 at 12:56 PM
biz.yahoo.com logoVOLITIONRX LTD Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Mat
biz.yahoo.com - October 11 at 7:46 PM
prnewswire.com logoVolitionRx Limited Announces Pricing of Public Offering of Common Stock
www.prnewswire.com - October 1 at 8:45 AM

Social

Chart

VolitionRX Ltd (VNRX) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.